Business Wire

CHINT

1.6.2022 11:26:08 CEST | Business Wire | Press release

Share
Boosting Green Energy Development: CHINT Exhibit in Hannover Provides Global Solution

Hannover Messe in Germany, the global industrial technology "wind vane", was held from May 30 to June 2. CHINT, the world's leading provider of smart energy solutions, presented 10 products and solutions, which covered new energy, green and environmentally friendly smart transformers, and smart buildings, at the Energy Solutions Pavilion (H11.C30).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005678/en/

Centered around new energy and the entire industry chain, CHINT shared its practices and exploration in the fields of "green energy", "smart grid”, "load reduction" and “new energy storage”. “CHINT is about green development and the forefront of carbon emission reduction in the electricity and energy sector. After all these years, CHINT has accumulated and established a great number of top clients and a rich set of user scenarios to rapidly perceive and capture changes and new demands in markets and clients,” said Lily Zhang, CEO of CHINT Electrics.

In 2021, CHINT and BYD's energy storage project orders were successfully delivered, and these two partners joined together to serve the new energy market in the UK. During that year, CHINT's Saudi Arabia smart meter project delivered more than 500,000 smart circuit breakers to local areas. CHINT Cambodia developed off-grid photovoltaic systems in local areas, providing electricity to local areas using thousands of off-grid photovoltaic installations.

CHINT’s solutions are aimed at energy transformation to help bring about global climate objectives. At the exhibition, CHINT’s exhibit featured 8 events delivered in online/offline mode, sharing CHINT's new products and solutions. CHINT shared photovoltaic solutions by having their European team put on a show for the audience so they could experience CHINT’s new energy solutions and photovoltaic applications across large-scale ground, industrial, commercial and residential fields. This showcased the attraction of the innovative "photovoltaic +" model. CHINT also shared its CHINT Smart City energy-saving, low-carbon, interconnected and efficient solutions to the audience. Meanwhile, CHINT’s smart terminal molded case circuit breakers, Arc Fault Detection Devices (AFDD), and a number of new products took center stage, showcasing the company’s strengths in smart manufacturing.

Lily Zhang believes that “through a trade exhibition platform as important as Hannover, clients from more than 140 different nations and regions around the world have joined with CHINT to engage in discussions and exchanges. The cooperation formed between CHINT and international partners is full of endless potential and will leverage the CHINT’s global solution to boost green energy development.”

ABOUT CHINT GLOBAL

CHINT Global is committed to serving as the world's leading provider of intelligent energy solutions for the whole industrial chain. After more than 2 decades of global expansion, our business and marketing network covers over 140 countries and regions worldwide, with a wide range of industries in low voltage electric, smart electrics, energy instruments and meters, green energy, etc.

As the localization progresses steadily, through business integration and industrial upgrade, CHINT Global will further open up the supply chain, optimize the service system, and establish an ecological mechanism, in order to provide innovative integrated technological service for the global energy market.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye